Acadia updated its full-year 2025 guidance, projecting earnings per share of $2.45 to $2.65, with the $2.55 midpoint falling below the analyst consensus of $2.62. The company expects revenue between ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...